(ALAB) Astera Labs, Common Stock - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US04626A1034
Retimers, Controllers, Switches, Modules, Software
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 94.8% |
| Value at Risk 5%th | 131% |
| Relative Tail Risk | -15.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.83 |
| Alpha | 11.94 |
| CAGR/Max DD | 2.30 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.522 |
| Beta | 2.348 |
| Beta Downside | 2.254 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.69% |
| Mean DD | 28.23% |
| Median DD | 31.05% |
Description: ALAB Astera Labs, Common Stock December 03, 2025
Astera Labs (NASDAQ: ALAB) is a U.S.–based semiconductor firm founded in 2017 that develops and sells connectivity solutions aimed at cloud-computing and artificial-intelligence (AI) infrastructure.
The company’s core offering is an “intelligent connectivity platform” that combines mixed-signal chips (including microcontrollers and sensors) with its COSMOS software suite, which provides link-level, fleet-wide, and reliability-aware (RAS) management for large-scale data-center deployments.
Product lines include PCIe/CXL smart retimers, Ethernet smart cable modules, CXL memory controllers, and smart fabric switches-components that enable high-bandwidth, low-latency communication between CPUs, GPUs, and accelerators in hyperscaler and OEM systems.
Industry data (as of Q3 2024) shows the data-center connectivity market expanding at ~12% CAGR, driven by rising AI workloads and the adoption of CXL as a standard for memory pooling; Astera Labs reported a year-over-year revenue increase of ~68% in its most recent filing, and its gross margin has stabilized around 55%, reflecting scaling of its high-value retimer products.
For a deeper, data-driven assessment of ALAB’s valuation relative to sector peers, you may find ValueRay’s analytical dashboard worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (198.9m TTM) > 0 and > 6% of Revenue (6% = 43.4m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 7.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 164.5% (prev 280.5%; Δ -116.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 263.7m > Net Income 198.9m (YES >=105%, WARN >=100%) |
| Net Debt (-109.1m) to EBITDA (171.6m) ratio: -0.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 12.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (180.6m) change vs 12m ago 15.18% (target <= -2.0% for YES) |
| Gross Margin 75.41% (prev 77.62%; Δ -2.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 60.65% (prev 31.10%; Δ 29.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.02 (EBITDA TTM 171.6m / Interest Expense TTM 16.6m) >= 6 (WARN >= 3) |
Altman Z'' 6.18
| (A) 0.85 = (Total Current Assets 1.29b - Total Current Liabilities 101.0m) / Total Assets 1.40b |
| (B) -0.02 = Retained Earnings (Balance) -34.6m / Total Assets 1.40b |
| (C) 0.14 = EBIT TTM 166.6m / Avg Total Assets 1.19b |
| (D) -0.24 = Book Value of Equity -30.5m / Total Liabilities 129.5m |
| Total Rating: 6.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.30
| 1. Piotroski 6.0pt |
| 2. FCF Yield 0.93% |
| 3. FCF Margin 31.73% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -0.64 |
| 6. ROIC - WACC (= -5.03)% |
| 7. RoE 18.02% |
| 8. Rev. Trend 90.96% |
| 9. EPS Trend 85.98% |
What is the price of ALAB shares?
As of December 12, 2025, the stock is trading at USD 173.70 with a total of 5,538,027 shares traded.
Over the past week, the price has changed by +13.89%, over one month by +3.67%, over three months by -25.42% and over the past year by +41.66%.
Over the past week, the price has changed by +13.89%, over one month by +3.67%, over three months by -25.42% and over the past year by +41.66%.
Is ALAB a buy, sell or hold?
Astera Labs, Common Stock has received a consensus analysts rating of 4.47.
Therefore, it is recommended to buy ALAB.
- Strong Buy: 9
- Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 198.3 | 14.2% |
| Analysts Target Price | 198.3 | 14.2% |
| ValueRay Target Price | 184.1 | 6% |
ALAB Fundamental Data Overview December 05, 2025
Market Cap USD = 25.76b (25.76b USD * 1.0 USD.USD)
P/E Trailing = 125.0
P/E Forward = 65.3595
P/S = 35.6244
P/B = 20.2541
Beta = None
Revenue TTM = 723.0m USD
EBIT TTM = 166.6m USD
EBITDA TTM = 171.6m USD
Long Term Debt = 1.29m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 4.44m USD (from shortTermDebt, last quarter)
Debt = 31.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.1m USD (from netDebt column, last quarter)
Enterprise Value = 24.65b USD (25.76b + Debt 31.3m - CCE 1.13b)
Interest Coverage Ratio = 10.02 (Ebit TTM 166.6m / Interest Expense TTM 16.6m)
FCF Yield = 0.93% (FCF TTM 229.4m / Enterprise Value 24.65b)
FCF Margin = 31.73% (FCF TTM 229.4m / Revenue TTM 723.0m)
Net Margin = 27.50% (Net Income TTM 198.9m / Revenue TTM 723.0m)
Gross Margin = 75.41% ((Revenue TTM 723.0m - Cost of Revenue TTM 177.8m) / Revenue TTM)
Gross Margin QoQ = 76.25% (prev 75.84%)
Tobins Q-Ratio = 17.60 (Enterprise Value 24.65b / Total Assets 1.40b)
Interest Expense / Debt = 53.09% (Interest Expense 16.6m / Debt 31.3m)
Taxrate = 36.27% (24.3m / 66.9m)
NOPAT = 106.2m (EBIT 166.6m * (1 - 36.27%))
Current Ratio = 12.78 (Total Current Assets 1.29b / Total Current Liabilities 101.0m)
Debt / Equity = 0.02 (Debt 31.3m / totalStockholderEquity, last quarter 1.27b)
Debt / EBITDA = -0.64 (Net Debt -109.1m / EBITDA 171.6m)
Debt / FCF = -0.48 (Net Debt -109.1m / FCF TTM 229.4m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.19% (Net Income 198.9m / Total Assets 1.40b)
RoE = 18.02% (Net Income TTM 198.9m / Total Stockholder Equity 1.10b)
RoCE = 15.08% (EBIT 166.6m / Capital Employed (Equity 1.10b + L.T.Debt 1.29m))
RoIC = 9.62% (NOPAT 106.2m / Invested Capital 1.10b)
WACC = 14.65% (E(25.76b)/V(25.79b) * Re(14.67%) + (debt cost/tax rate unavailable))
Discount Rate = 14.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.83%
[DCF Debug] Terminal Value 57.92% ; FCFE base≈174.3m ; Y1≈175.2m ; Y5≈187.7m
Fair Price DCF = 8.54 (DCF Value 1.44b / Shares Outstanding 168.9m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: 85.98 | EPS CAGR: 123.4% | SUE: 1.68 | # QB: 2
Revenue Correlation: 90.96 | Revenue CAGR: 118.2% | SUE: 3.54 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.52 | Chg30d=+0.079 | Revisions Net=+12 | Analysts=17
EPS next Year (2026-12-31): EPS=2.37 | Chg30d=+0.278 | Revisions Net=+13 | Growth EPS=+33.3% | Growth Revenue=+42.2%
P/E Trailing = 125.0
P/E Forward = 65.3595
P/S = 35.6244
P/B = 20.2541
Beta = None
Revenue TTM = 723.0m USD
EBIT TTM = 166.6m USD
EBITDA TTM = 171.6m USD
Long Term Debt = 1.29m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 4.44m USD (from shortTermDebt, last quarter)
Debt = 31.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.1m USD (from netDebt column, last quarter)
Enterprise Value = 24.65b USD (25.76b + Debt 31.3m - CCE 1.13b)
Interest Coverage Ratio = 10.02 (Ebit TTM 166.6m / Interest Expense TTM 16.6m)
FCF Yield = 0.93% (FCF TTM 229.4m / Enterprise Value 24.65b)
FCF Margin = 31.73% (FCF TTM 229.4m / Revenue TTM 723.0m)
Net Margin = 27.50% (Net Income TTM 198.9m / Revenue TTM 723.0m)
Gross Margin = 75.41% ((Revenue TTM 723.0m - Cost of Revenue TTM 177.8m) / Revenue TTM)
Gross Margin QoQ = 76.25% (prev 75.84%)
Tobins Q-Ratio = 17.60 (Enterprise Value 24.65b / Total Assets 1.40b)
Interest Expense / Debt = 53.09% (Interest Expense 16.6m / Debt 31.3m)
Taxrate = 36.27% (24.3m / 66.9m)
NOPAT = 106.2m (EBIT 166.6m * (1 - 36.27%))
Current Ratio = 12.78 (Total Current Assets 1.29b / Total Current Liabilities 101.0m)
Debt / Equity = 0.02 (Debt 31.3m / totalStockholderEquity, last quarter 1.27b)
Debt / EBITDA = -0.64 (Net Debt -109.1m / EBITDA 171.6m)
Debt / FCF = -0.48 (Net Debt -109.1m / FCF TTM 229.4m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.19% (Net Income 198.9m / Total Assets 1.40b)
RoE = 18.02% (Net Income TTM 198.9m / Total Stockholder Equity 1.10b)
RoCE = 15.08% (EBIT 166.6m / Capital Employed (Equity 1.10b + L.T.Debt 1.29m))
RoIC = 9.62% (NOPAT 106.2m / Invested Capital 1.10b)
WACC = 14.65% (E(25.76b)/V(25.79b) * Re(14.67%) + (debt cost/tax rate unavailable))
Discount Rate = 14.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.83%
[DCF Debug] Terminal Value 57.92% ; FCFE base≈174.3m ; Y1≈175.2m ; Y5≈187.7m
Fair Price DCF = 8.54 (DCF Value 1.44b / Shares Outstanding 168.9m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: 85.98 | EPS CAGR: 123.4% | SUE: 1.68 | # QB: 2
Revenue Correlation: 90.96 | Revenue CAGR: 118.2% | SUE: 3.54 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.52 | Chg30d=+0.079 | Revisions Net=+12 | Analysts=17
EPS next Year (2026-12-31): EPS=2.37 | Chg30d=+0.278 | Revisions Net=+13 | Growth EPS=+33.3% | Growth Revenue=+42.2%
Additional Sources for ALAB Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle